T he prevalence of MDD is estimated at 4.4% worldwide, 1 high rates of treatment resistance: fewer than 40% will achieve remission during an initial course of treatment . 2, 3 In older adults, the consequences of depression, including cognitive decline, 4 greater healthcare use, 5 functional decline, 6, 7 and greater overall mortality, 8 have prompted an aggressive search for predictors of therapeutic response, such as cerebrovascular disease, 9 ,10 genetic factors, 11 peripheral biomarkers, and symptomatic phenotypes. 12, 13 It was recently demonstrated 14 that management of depression reduces mortality in older adults with multimorbidity and depression.
Metabolic syndrome (MetS) is defined as a combination of obesity and two or more of the following components: hypertension, high triglycerides, low high-density lipoprotein (HDL-C), and fasting hyperglycemia. 15 It has been postulated that MetS affects the prevalence and severity of depressive disorders. 16, 17 The association is bidirectional, with depression predicting MetS and vice versa.
ages have yielded varied results; one study 18 found no association between MetS and treatment resistance, whereas two others 19 and 20 associated treatment resistance with metabolic dysfunction but did not evaluate MetS specifically.
Treatment response in late-life depression (LLD) might be particularly linked to MetS, because both conditions are highly prevalent in older adults, share a variety of mechanistic links, 21 and result in shared downstream effects, including cardiovascular and cerebrovascular sequelae. 22, 23 Only two studies have examined the course of LLD in the context of MetS. One 24 found that MetS (but no individual MetS components) predicted depression chronicity. The other 25 also found that MetS predicted a chronic course of depression but not after multivariate adjustment; number of MetS components, waist circumference, and HDL-C were predictive of depression chronicity as well. A limitation of both studies is that the treatment of LLD was not standardized or well described, so these studies could not evaluate the association between MetS and treatment resistance.
The Incomplete Response in Late Life Depression: Getting to Remission (IRL GRey) study was conducted to better inform therapy for treatment-resistant depression in older adults. 26 Participants aged 60 and older with MDD were treated with open-label venlafaxine extended-release (XR) 150 to 300 mg/d for 12 weeks; nonremitters were then randomized 1:1 to receive aripiprazole or placebo. When the study was initiatially conceived, the concept of metabolic depression had not been fully explored in the literature, but during the course of the study, it became clear that components of metabolic syndrome may affect depression treatment response. Data from the initial phase of treatment with venlafaxine offered a prime opportunity to test the hypothesis that, in older adults in North America (where MetS is prevalent), comorbid MetS may predict poorer response to treatment of MDD. Based on the aforementioned associations between MetS and depression, we hypothesized that the presence of MetS would predict a prolonged time to remission from depression (primary hypothesis); participants with more MetS components would have a prolonged time to remission; given the central role of insulin resistance in MetS and the multiple pathophysiological links between diabetes mellitus and MDD, 27 a surrogate measure of insulin resistance, the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) value, would also be independently associated with a prolonged time to remission.
METHODS

Description of Parent Study
Inclusion criteria for IRL GRey were aged 60 and older with nonpsychotic MDD and a MADRS score of 15 or higher. 26 Exclusion criteria included dementia or other cognitive impairment evidenced by a Mini-Mental Status Examination (MMSE) score of 20 or less, 28 bipolar disorder, schizophrenia, schizoaffective disorder, psychosis, alcohol or substance misuse or dependence in the preceding 6 months, and unstable medical illness. Participants were recruited at the University of Pittsburgh, the Centre for Addiction and Mental Health in Toronto, and Washington University in St Louis from July 2009 to December 2013. Respective site institutional review boards approved the study protocol, and all participants provided written, informed consent. Further details on sample-size determination, recruitment, enrollment, randomization, assessments, procedures, and safety review are available elsewhere. 26 
Assessments
MADRS assesses the severity of 10 depressive symptoms, with a total score ranging from 0 (absence of any depressive symptoms) to 60 (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). 29 Presence of MetS was determined at baseline using the International Diabetes Federation (IDF) worldwide consensus definition, which requires central obesity based on body mass index (BMI) or waist circumference (WC) (see below) and two or more of high triglyceride levels, low HDL-C, high blood pressure, and high fasting plasma glucose. 15 Obesity was defined as a BMI of 30.0 kg/m 2 or more or by reaching a sex-specific waist circumference cutoff (≥80 cm in women of all races and ethnicities, ≥90 for South Asian, Japanese and Chinese men or ≥94 cm in Caucasian men). High triglyceride level was defined as 150 mg/dL (1.7 mmol/L) or greater or specific treatment. Low HDL-C was defined as less than 40 mg/dL (1.03 mmol/L) in men or less than 50 mg/dL (1.29 mmol/L) in women or specific treatment. High blood pressure was defined as systolic blood pressure (SBP) of 130 mmHg or greater, diastolic blood pressure (DBP) of 85 mmHg or greater, or treatment for hypertension. High fasting glucose was defined as a fasting plasma glucose of 100 mg/dL (5.6 mmol/L) or greater or previously diagnosed diabetes mellitus type 2. Waist circumference was determined by measuring halfway between the inferior margin of the ribs and the iliac crest. Weight and height were determined with light clothing on, shoes removed, and pockets emptied. Blood pressure was measured seated after 5 minutes of rest. In cases in which multiple baseline readings of these parameters were made, data that most closely preceded initiation of treatment were used. History of hypertension, diabetes mellitus, low HDL-C, or hypertriglyceridemia and active pharmacotherapy for the same were assessed according to participant report. According to IDF recommendations, individuals meeting criteria for these MetS components according to history or medication use were included in our analyses. Blood samples were drawn from participants in a fasting state. HOMA-IR was calculated as follows: (fasting insulin (lU/mL)) 9 (fasting glucose (mg/dL))/405. 30 
Procedures
Open-label venlafaxine XR was initiated at 37.5 mg/d in all participants and uptitrated in increments of 37.5 mg/d after a minimum of 3 days, targeting 150 mg/d. After 6 weeks of treatment, if MADRS score remained greater than 10, venlafaxine dosage was increased by increments of 37.5 to 75 mg/d over at least 3 days based on clinical response and as symptomatically tolerated, up to a maximum dose of 300 mg/d. Those experiencing side effects underwent slower titration or received a lower dose. MADRS score was re-assessed at in-person follow-up visits every 1 to 2 weeks. After 12 weeks (or longer, if necessary, to allow for 4 weeks on the highest-tolerated dose of venlafaxine or to clarify remission status), participants were categorized as having remitted or not, with remission defined as reaching a MADRS score 10 or less for the last 2 follow-up visits. Participants were allowed to continue outside psychotherapy and medications for anxiety or sleep.
Statistical Analysis
Differences in baseline characteristics between those with and without MetS were evaluated using a two-tailed t-test or Wilcoxon test for continuous variables and a chi-square or Fisher exact test for categorical variables. The association between MetS status and remission from depression was assessed using the chi-square test. For our primary hypothesis, Cox proportional hazards regression was used to test for effect of MetS status on time to remission. In this model, a longer time to remission corresponds to a lower hazard ratio for remission. Univariate proportional hazards regression models were similarly created for each metabolic variable listed in Table 1 to investigate effect on time to remission. Then, MetS status, individual values for metabolic paramters, and treatment with antihypertensive and lipid-and glucose-lowering agents were included separately in an adjusted model. The adjusted model included demographic and depression-related variables found in stepwise proportional hazards regression to predict time to remission at a significance level of .05. The variables evaluated for predictive effect were age, sex, education, living status (alone or with others), study site, referral source, outside psychotherapy, baseline total MADRS score, duration of current depressive episode (dichotomized to > or ≤ 2 years), recurrent depression or single episode, MMSE, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS, 31 score, and prior antidepressant treatment assessed using the Antidepressant Treatment History Form (ATHF) 32 as dichotomized to 2 or less (no prior adequate antidepressant trial in this depressive episode) or 3 or greater (≥1 adequate trials). Because obstructive sleep apnea has been previously associated with treatment resistance in this sample, 33 this analysis was not repeated here. Analyses were performed on SAS version 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS
Participant Characteristics
Of 435 participants with MDD beginning venlafaxine (Table 1) , 211 did not meet criteria for MetS, 222 met criteria for MetS, and 2 could not be classified because of missing data. The MetS group had greater baseline symptom severity as measured using total MADRS and Hamilton Rating Scale for Depression (HRSD) 34 scores and MADRS symptom scores for reported sadness, reduced sleep, and lassitude, and greater duration of depressive episode; site distribution varied according to MetS status, as well. The majority of our sample had been previously treated for their current depressive episode, with 59.1% having received an adequate course of antidepressant treatment corresponding to an ATHF score of 3 or more, with trendline ATHF score observed in those with MetS. Measures of most metabolic parameters differed according MetS status as expected, except low-density lipoprotein cholesterol (LDL-C) and total cholesterol, which were higher in the group without MetS. Those with MetS also had greater medical illness burden as measured using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) 35 and greater prevalence of cardiovascular disease. The groups were similar in all other baseline characteristics (Table 1) .
Relationship Between MetS and Remission
Of the participants in the parent study, 182 (41.8%) reached a sustained MADRS score of 10 or less (remission), 160 did not remit, and 93 left the study before completing 12 weeks of therapy ( Figure 1 ). Those with MetS were less likely to remit (36.9%) than those without MetS (46.5%, chi-square = 4.03, degrees of freedom (df) = 1, P = .04). There was no difference in proportion of participants withdrawing from the study according to MetS status (21.6% vs 21.3%, chi-square = 0.0056, df = 1, P = .94).
Univariate Cox proportional hazards regression demonstrated greater time to remission in participants with MetS (hazard ratio (HR) = 0.71, 95% confidence interval (CI) = 0.52-0.95, P = .02; Table 2 
Individual Metabolic Variables As Predictors of Time to Remission
Univariate proportional hazard regression models found that higher HDL-C levels (HR = 1.11 per 10 mg/dL, 95% CI = 1.02-1.21) predicted shorter time to remission, whereas higher DBP (HR = 0.88 per 10 mmHg, 95% CI = 0.77-0.995) and more MetS components (HR = 0.89 per component, 95% CI = 0.80-0.99) predicted greater time to remission. Upon introduction to the adjusted model, only DBP (HR = 0.87 per 10 mmHg increase, 95% CI = 0.77-0.99) remained a significant predictor. HOMA-IR was not a significant predictor of time to remission in univariate or adjusted models (Table 2) . Cerebrovascular disease, cardiovascular disease, and smoking were not predictive of time to remission.
We also examined whether medications targeting blood pressure, lipids, and glucose would confound analyses of these metabolic parameters' effects on time to remission by inserting each as an individual variable in the JAGS DECEMBER 2017-VOL. 65, NO. 12 EFFECT OF METABOLIC SYNDROME ON LATE-LIFE DEPRESSION univariate model, without adjustments for disease-related and demographic variables, and found no such effects (data not shown). Use of co-prescribed beta-blockers, or any antihypertensives, had no effect on time to remission for DBP (which remained significant) or SBP or pulse pressure (which remained nonsignificant). HDL-C remained significant after adjusting for use of lipid-lowering drugs, and LDL-C, total cholesterol, and triglycerides remained nonsignificant. Finally, no moderating effect was found of use of glucose-lowering drugs and insulin, glucose, or HOMA-IR on time to remission, with all remaining nonsignificant (data not shown).
DISCUSSION
In this study of older adults with MDD, we evaluated the effect of MetS on remission with antidepressant treatment.
To our knowledge, our study is the first to examine this relationship in older adults, as well as the first to do so in a North American population with a high prevalence of MetS. We had three importatn findings. First, MetS was associated with more-severe depression, including greater symptom severity and longer duration of depression. Second, the presences of MetS was associated with a longer time to remission of depressive symptoms during antidepressant treatment, although the relationship was no longer significant after controlling for these severity markers. In other words, the greater severity of depression observed in individuals with MetS appears to account for their poorer treatment response. Third, having more MetS components and lower HDL-C predicted greater time to remission but not after multivariate adjustment; only higher DBP predicted greater time to remission, with and without inclusion of covariates. Although two previous studies (Vogelzangs et al. 19 and Marijnissen et al. 25 ) found number of MetS components and low HDL-C to predict chronicity of depression, to our knowledge, such an effect of DBP on chronicity or treatment response in depression has not been previously reported. Moreover, DBP was the only variable to remain significant in our adjusted analyses. These results tentatively link high DBP with treatment-resistant depression. Cerebrovascular disease burden could be one mediator of such an effect. Hypertension is an established risk factor for vascular depression, 36 but its relationship with LLD more broadly has not been proven. 37 There are no universally accepted diagnostic criteria for vascular depression, but it is generally characterized by later age of onset than other types of depression, and in the settting of atherosclerotic risk factors and radiographic evidence of cerebrovascular disease. 10, 38 Clinical features include psychomotor slowing, apathy, and greater cognitive impairment than found in other forms of LLD, with greater risk of treatment failure, progression to dementia, and mortality. 10 High DBP could also denote hypothalamic-pituitary-adrenal axis 
Limitations and Strengths
A primary limitation of our study concerns the associations observed between MetS and greater symptom severity, longer duration of depressive episode, and trendline ATHF score. Given the cross-sectional nature of the baseline data, causality cannot be assessed. Literature on association between the MetS and depressive symptom severity has been equivocal, with some, 40, 41 but not all, 25 previous authors reporting a positive relationship. Other collinear effects could also partly explain the effect of MetS on time to remission; for example, obstructive sleep apnea, a potent predictor of resistance to antidepressant treatment in this same study population, 33 was highly correlated with MetS status in our sample.
We were unable to detect an effect of insulin concentration or HOMA-IR on remission, despite well-known epidemiological and mechanistic links between diabetes mellitus, insulin resistance and depression. 27 HOMA-IR is a well-validated surrogate measure of insulin resistance in large populations and is correlated with more-sensitive measures in younger populations, 42 although it may have limited utility to detect age-related insulin resistance in smaller populations, particularly in older adults. 43 It is likely that this, in addition to missing insulin samples for a portion of study participants (Table 1) , limited the power to detect effects of insulin resistance on treatment response in late-life depression.
Racial and ethnic minorities were not well represented in the study sample, decreasing generalizability of our findings to nonwhite populations. These results should be interpreted with caution, because race has been shown to modulate obesity's effects on prevalence of depression. 44, 45 Inclusion of individuals in the MetS group who had the requisite number of MetS components because of medical history and treatment of low HDL-C, high triglycerides, hypertension, or diabetes mellitus, in accordance with IDF criteria for MetS, in our analytical model could have increased the likelihood of type 2 error. Additionally, although higher DBP could prolong time to remission by increassing cerebrovascular disease burden, no cerebral imaging was available to correlate cerebrovascular disease markers with metabolic derangement and treatment response. Finally, use of venlafaxine in a highly standardized dosing algorithm by all participants is a weakness and strength. Although the generalizability of these results to other antidepressants is unknown, more-reliable comparisons between participants can be drawn. A recent metaanalysis of treatment studies for MDD in older adults demonstrated greater efficacy of sertraline, paroxetine, and duloxetine than of placebo, which was not the case for venlafaxine in the sole included study featuring venlafaxine; metabolic variables were not discussed or adjusted for. 46 The sample was metabolically well characterized and might offer useful insights into the relationship between MetS, other metabolic variables, and depression treatment response. Other study strengths include a fairly large sample of older adults with MDD and a high prevalence of MetS from three sites in North America, lending greater generalizability to the study's findings.
In conclusion, we report an association between MetS and poorer antidepressant response in elderly persons with MDD, which greater symptom severity and duration of depression at baseline appears to account for. Randomized, prospective depression treatment studies measuring For continuous and numerical variables, hazard ratios (HRs) reflect increasing number of the stated variable, with a lower HR = corresponding to less incidence of remission and thus greater time to remission. For binary variables (metabolic syndrome, cardiovascular disease, cerebrovascular disease, smoking), the HR = presented is that for presence of the stated entity versus absence of the stated entity.
metabolic and depressive outcomes are indicated to better understand the causal relationship between MetS, depression severity, and treatment response. Of individual MetS components, DBP remained a significant predictor of treatment outcome after multivariate adjustment. The results of this study should be interpreted with caution. We do not recommend that clinicians treat older adults with depression differently in the face of co-occuring MetS. Further verification of these findings is indicated using more-reliable markers of insulin resistance and other classes of antidepressants in racially diverse populations in the hopes of better informing treatment decisions in LLD.
